BioProcess Insider

Robust risk management can offset supply chain problems that have been further aggravated by COVID-19, says Samsung Bioepis’ Thomas Newcomer.

Hanmi Fine Chemical says the COVID-19 pandemic has increased the demand for RNA raw materials, causing it to launch CDMO services in relevant fields.

There is no lack of talented women in the biotech space but the gates blocking their progression must be open for them to fully realize their potential, says consultant Nadine Ritter.

With the cost of manufacturing accounting for as much as 70% for cell and gene therapies, industry must look to bioprocessing efficiencies and collaboration, says Waters Corporation.

Inherent challenges to traditional flu vaccine manufacturing can easily be overcome with messenger RNA (mRNA) says Moderna, which is moving a candidate into Phase III trials.

Autologous therapies have not kept up with demand says Allogene Therapeutics, which claims only off-the-shelf cell therapies can serve larger patient populations.

Cell therapy developers need uniform handling, storage, and usage methods say the authors of a new report examining how the market for centrally manufactured products is evolving.

Northway will open a facility in Waltham offering microbial and mammalian cell line development and upstream and downstream process advancement.

Lotte is set to buy Bristol-Myers Squibb’s (BMS) facility in East Syracuse, which it says will serve its CDMO business in the US.

The Philadelphia-based CDMO will expand its capacity in sterile lyophilization technology and aseptic liquid fill/finish to stay ahead of demand.

Bayer says a three-year production reorganization will modernize its manufacturing network and streamline its supply chain, but specific details remain scarce.

Merck & Co. has added 120,000 square feet of manufacturing capacity at its Rockingham County site to support continued scale-up of its Gardasil HPV vaccines.

Abzena has secured $65 million in additional funding to expand its production facilities to meet the increased demand in the industry.

ThermoGenesis has leased a facility in Sacramento, California to house its newly launched CDMO cell therapy business TG Biosynthesis.

CGT Catapult says the UK is a “world leader” in developing advanced therapies after publishing a 2021 clinical trials database and report.

Voices of Biotech, Informa Connects latest podcast focuses on celebrating diverse leaders driving change within the life science industry. Through interviews and discussions, we explore the careers of key female leaders, how the industry is evolving, what progress has been made, and what more can be done to create gender and diversity parity within biotech.